We performed next generation sequencing (NGS) of TP53 exons 4-9 on genomic DNA of 151 primary patients with plasma cell dyscrasia, including 129 MM and 12 primary PCL (pPCL) patients at diagnosis, and 10 secondary PCL (sPCL) cases (median depth of coverage = 162x). This evidence concerns the gene TP53 and Miyoshi myopathy.